https://orcid.org/0000-0002-0090-6289
References
- Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516.
- Luba KM, Stulberg DL. Chronic plaque psoriasis. Am Fam Physician. 2006;73(4):636–644.
- Armstrong AW, Koning JW, Rowse S, et al. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther (Heidelb). 2017;7(1):97–109.
- Han C, Lofland JH, Zhao N, et al. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2011;10(8):843–850.
- Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323–332.
- Lewis-Beck C, Abouzaid S, Xie L, et al. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013;7:199–205.
- Korman NJ, Zhao Y, Pike J, et al. Increased severity of itching, pain, and scaling in psoriasis patients is associated with increased disease severity, reduced quality of life, and reduced work productivity. Dermatol Online J. 2015;21(10):13030.
- Yu AP, Tang J, Xie J, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin. 2009;25(10):2429–2438.
- Schaefer CP, Cappelleri JC, Cheng R, et al. Health care resource use, productivity, and costs among patients with moderate to severe plaque psoriasis in the United States. J Am Acad Dermatol. 2015;73(4):585–593.
- de Carvalho AV, Duquia RP, Horta BL, et al. Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: a systematic review and meta-analysis of randomized clinical trials. Drugs R D. 2017;17(1):29–51.
- Institute for Clinical and Economic Review. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: condition update. Final Evidence Report. 2018. [cited 2018 Sep 10]. Available from: https://icer-review.org/wp-content/uploads/2017/11/ICER_Psoriasis_Update_Final_Evidence_Report_080118.pdf.
- Institute for Clinical and Economic Review. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. Final Evidence Report. 2016. [cited 2017 Jul 22]. Available from: https://icer-review.org/wp-content/uploads/2016/11/NE_CEPAC_Psoriasis_Evidence_Report_FINAL_012317.pdf.
- Hendrix N, Ollendorf DA, Chapman RH, et al. Cost-effectiveness of targeted pharmacotherapy for moderate to severe plaque psoriasis. J Manag Care Spec Pharm. 2018;24(12):1210–1217.
- Wu JJ, Feldman SR, Rastogi S, et al. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatolog Treat. 2018;29(8):769–774.
- Feldman SR, Zhao Y, Navaratnam P, et al. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(3):201–209.
- Gniadecki R, Bang B, Bryld LE, et al. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172(1):244–252. Jan
- Arias E, Heron M, Xu J. United States Life Tables, 2013. Natl Vital Stat Rep. 2017;66(3):1–64.
- Micromedex: Thomson Reuters. Red Book Online. [cited 2019 May 14]. Available from: http://www.micromedexsolutions.com.
- Celgene Corporation. Apremilast (Otezla) prescribing information. 2017. [cited 2017 Jul 26]. Available from: https://www.celgene.com/content/uploads/otezla-pi.pdf.
- Janssen Biotech. Guselkumab (Tremfya) prescribing information. 2017. [cited 2017 Jul 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf.
- Valeant Pharmaceuticals North America LLC. SILIQ (brodalumab) prescribing information. 2017. [cited 2017 Jul 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf.
- Eli Lilly and Company. Ixekizumab (Taltz) prescribing information. 2017. [cited 2017 Jul 26]. Available from: https://pi.lilly.com/us/taltz-uspi.pdf.
- Novartis Pharmaceuticals Corporation. Secukinumab (Cosentyx) prescribing information. 2017. [cited 2017 Jul 26]. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf.
- UBC, Inc. Certolizumab pegol (Cimzia) prescribing information. 2017. [cited 2017 Jul 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125160s270lbl.pdf.
- Centers for Medicare and Medicaid Services. Physician fee schedule. 2017. [cited 2017 Sep 25]. Available from: https://www.cms.gov/apps/physician-fee-schedule/.
- National Institute for Health and Care Excellence. Single technology appraisal. Secukinumab for treating moderate to severe plaque psoriasis [TA350]. 2015. [cited 2017 Jul 27]. Available from: https://www.nice.org.uk/guidance/ta350.
- Center for Medicare and Medicaid Services. National and State Summaries of Inpatient Charge Data, FY2015. 2017. [cited 2017 Oct 3]. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/Inpatient2015.html.